Antibiotics in endophthalmitis: Microbiological and pharmacokinetic considerations

Current Clinical Pharmacology

Volumn 5, Issue 1, 2010, Pages 47-54

  López Cabezas, Carmen ^a   Muner, Dolors Soy ^a   Massa, Merce Roca ^a   Pueyo, Josep M Mensa ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antibiotics; Endophthalmitis; Intravitreal administration; Vitreous cavity

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFPIROME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; DEXAMETHASONE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AQUEOUS HUMOR; BACILLUS CEREUS; BACTERIAL EYE INFECTION; BACTERICIDAL ACTIVITY; BLOOD EYE BARRIER; CANDIDA; CANDIDA ALBICANS; CELL DESTRUCTION; DIFFUSION; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG PENETRATION; ENDOPHTHALMITIS; EYE FUNDUS; HAEMOPHILUS INFLUENZAE; HUMAN; INFLAMMATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; RETINA INJURY; REVIEW; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC THERAPY; TOPICAL TREATMENT; VITREOUS BODY;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; ENDOPHTHALMITIS; HUMANS; INJECTIONS; OPHTHALMIC SOLUTIONS; PERMEABILITY; RETINAL DISEASES; VITREOUS BODY;

EID: 77950799869     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410790410597     Document Type: Review

References (55)

1. Nagar M, Sivaprasad S, Kapoor B. Antibiotics for treating postoperative endophthalmitis after cataract surgery (Protocol). The Cochrane Library 2008.
2. Lynn WA, Lightman S. The eye in systemic infection. Lancet 2004; 364: 1439-1450
3. Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM. Endogenous Endophthalmitis. An 18-year review of culture-positive cases at a tertiary care centre. Medicine 2003; 82; 97-105.
4. Snyder RW, Glasser DB. Antibiotic therapy for ocular infection. West J Med 1994; 161(6): 579-584
5. Albert DM, Jakobiec FA. Endogenous endophthalmitis. In: Principles and Practice of Ophthalmology. WB Saunders Co 1994; vol.5: pp. 3120-3125
6. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131-1135
7. Lalwani GA, Flynn HW Jr, Scott IU, et al. Acute-onset endoph-thalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology 2008; 115(3): 473-476
8. Thompson WS, Rubsamen PE, Flynn HW Jr, Schiffman J, Cousins SN. Endophthalmitis after penetrating trauma: Risk factors and visual acuity outcomes. Ophthalmology 1995; 102: 1696-1701
9. Norregaard JC, Thoning H, Bernth-Petersen P, Andersen TF, Javitt JC, Anderson GF. Risk of endophthalmitis after cataract extraction: Results from the International Cataract Surgery Outcomes study. Br J Ophthalmol 1997; 81(2): 102-106 (Pubitemid 27092486)
10. O'Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: Potential role of moxi-floxacin. J Cataract Refract Surg 2007; 33(10): 1790-1800
11. Wejde G, Samolov B, Seregard S, Koranyi G, Montan PG. Risk factors for endophthalmitis following cataract surgery: a retrospective case-control study. J Hosp Infect 2005; 61(3): 251-256
12. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996; 122: 1-17.
13. Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: A systematic review of the literature. Arch Ophthalmol 2005; 123(5): 613-620 (Pubitemid 40695508)
14. Aldave AJ, Stein JD, Deramo VA, Shah GK, Fischer DH, Maquire JI. Treatment strategies for postoperative Propionibacterium acnes endophthalmitis. Ophthalmology 1999; 106(12): 2395-2401
15. Miller JJ, Scott IU, Flynn HW Jr, et al. Endophthalmitis caused by Bacillus species. Am J Ophthalmol 2008; 145(5): 883-888
16. Okada AA, Johnson RP, Liles WC, D'Amico DJ, Baker AS. Endogenous bacterial endophthalmitis. Report of a ten-year retrospective study. Ophthalmology 1994; 101(5): 832-838
17. Warheker P, Gupta S, Mansfield D, Seal DV. Successful treatment of saccular endophthalmitis with clarithromycin. Eye 1998; 12:1017-1019
18. Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol 1979;23(5): 279-296
19. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007; 4(4): 371-388
20. Liu W, Liu QF, Perkins R, et al. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: Physicochemical properties that regulate penetration of quinolone antimicrobials. Antimicrob Agents Chemother 1998; 42(6): 1417-1423
21. Coco RM, Lopez MI, Pastor JC, Nozal MJ. Pharmacokinetics of intravitreal vancomycin in normal and infected rabbit eyes. J Ocul Pharmacol Ther 1998; 14(6): 555-563
22. Oztürk F, Kortunay S, Kurt E, et al. Effects of trauma and infection on ciprofloxacin levels in the vitreous cavity. Retina 1999; 19(2):127-130
23. Oztürk F, Kortunay S, Kurt E, et al. Ofloxacin levels after intravitreal injection. Effects of trauma and inflammation. Ophthalmic Res 1999; 31(6): 446-451
24. Axelrod JL, Klein RM, Bergen RL, Sheikh MZ. Human vitreous levels of selected antistaphylococcal antibiotics. Am J Ophthalmol 1985; 100: 570-575
25. Axelrod Jl, Newton JC, Klein RM, Bergen RL, Sheikh MZ. Penetration of imipenem into human aqueous and vitreous humor. Am J Ophthalmol 1987; 104: 649-653
26. Martinelli D, Mazzei T, Fallani S, Palendri G, Novelli A, Periti P. Ceftizoxime concentrations in human aqueous humor following intravenous administration. Chemioterapia 1998; 7: 317-319
27. Robinet A, Le Bot MA, Colin J, Riche C. Penetration of piperacillin into the vitreous after intravenous administration. Retina 1998;18: 526-530
28. Egger SF, Alzner E, Georgopoulos M, et al. Penetration of cefpirome into the anterior chamber of the human eye after intravenous administration. J Antimicrob Chemother 2000; 45: 213-216
29. Meredith TA, Aguilar HE, Shaarawi A, Kincaid M, Dick J, Niesman MR. Vancomycin levels in the vitreous cavity after intravenous administration. Am J Ophthalmol 1995; 119: 774-778
30. García E, Mensa J, López Y, et al. Penetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administration. Antimicrob Agents Chemother 2004; 48: 670-672
31. Fiscella RG, Lai WW, Buerk B, et al. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. Ophthalmology 2004; 111: 1191-1195
32. Ciulla TA, Comer GM, Peloquin C, Wheeler J. Human vitreous distribution of linezolid after a single oral dose. Retina 2005; 25:619-624
33. Horcajada JP, Atienza R, Sarasa M, Soy D, Adan A, Mensa J. Pharmacokinetics of linezolid in human non-inflamed vitreous after systemic administration. J Antimicrob Chemother 2009; 63(3):550-552
34. Ghazi-Nouri SM, Lochhead J, Mearza AA, et al. Penetration of oral and topical ciprofloxacin into the aqueous humour. Clin Exp Ophthalmol 2003; 31: 40-43
35. Behrens-Baumann W, Martell J. Ciprofloxacin concentrations in human aqueous humor following intravenous administration. Chemotherapy 1987; 33: 328-330
36. Hanioglu-Kargi S, Basci N, Soysal H, Bazkurt A, Gürsel E, Kayaalp O. The penetration of ofloxacin into human aqueous humor given by various routes. Eur J Ophthalmol 1998; 8: 33-36
37. Donnenfeld ED, Perry HD, Synder RB, Moadel R, Elsky M, Jones H. Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol 1997; 115: 173-176
38. Fiscella RG, Nguyen TKP, Cwik MJ, et al. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999; 106: 2286-2290
39. Hariprasad SM, Mieler WF, Holf ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol 2003; 121: 345-350
40. Kampougeris G, Antoniadou A, Kavouklis E, Chryssouli Z, Giamarellou H. Penetration of moxifloxacin into the human aqueous humor after oral administration. Br J Ophthalmol 2005; 89: 628-631
41. Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, Carrasco-Font C. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. J Cataract Refract Surg 2001; 27:1969-1974
42. Garcia-Vázquez E, Mensa J, Sarasa M, et al. Penetration of levofloxacin into the anterior chamber (aqueous humour) of the human eye after intravenous administration. Eur J Clin Microbiol Infect Dis 2007; 26(2): 137-140
43. Perdriel A, Chedru-Legros V, Miocque S. Intravitreal injections: A review. Eur J Hosp Pharm Pract 2008; 14: 48-50.
44. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: A comprehensive review. Retina 2004; 24(5):676-698
45. Davey P, Barza M, Stuart M. Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamycin and imipenem: evidence for resistance to "late" treatment infections. J Infect Dis 1987; 155: 518-523
46. Soy D, Torres A. Antibacterial dosage in intensive-care-unit patients based on pharmacokinetic/pharmacodynamic principles. Curr Opin Crit Care 2006; 12(5): 477-482
47. De Caro JJ, Ta CN, Ho HK, et al. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. Retina 2008; 28(6): 877-883
48. Alonso JM. Preparación de medicamentos y formulación magistral para Oftalmología. Madrid. Díaz de Santos 2003.
49. Ejdervick-Lindblad B, Lindberg M, Hakansson EB. Enterococcal endophthalmitis following cataract extraction, treated with ampicillin intravitreally. Acta Ophthalmol(Copenh) 1992; 70: 842-843
50. Hansen KD, Meyer RF. Amikacin treatment of pseudomonas caused corneal ulcer. Arch Ophthalmol 1980; 98: 1991-1992
51. Peyman GA. Antibiotic administration in the treatment of bacterial endophthalmitis. Intravitreal injections. Surv Ophthalmol 1977; 21:339-346
52. Endophthalmitis Vitrectomy Study Group. Results of the endoph-thalmitis vitrectomy study: A randomised trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995; 13: 1479-1496
53. Deghmane AE, Alonso JM, Taha MK. Emerging drugs for acute bacterial meningitis. Expert Opin Emerg Drugs 2009; 14(3): 381-393
54. Ogino H, Fujii M, Ono M, et al. In vivo and in vitro effects of fluoroquinolones on lipopolysaccharide-induced proinflammatory cytokine production. J Infect Chemother 2009; 15(3): 168-173
55. Gan IM, Ugahary LC, van Dissel JT, et al. Intravitreal dexametha-sone as adjuvant in the treatment of postoperative endophthalmitis: A prospective randomized trial. Graefes Arch Clin Exp Ophthalmol 2005; 243(12): 1200-1205